Genomic alterations in FSHD clearly implicate DUX4 (Himeda & Jones, 2019), leading to a statement in most recent FSHD publications to the effect: “mis‐expression of DUX4 underlies FSHD pathology”, and generally highlighting DUX4 as a therapeutic target. This evidence concerns the gene DUX4 and Facioscapulohumeral dystrophy.